Strides Pharma Rating
Macquarie on Strides Pharma - 28.05.2021
* Build a meaningful recovery beyond 1QFY22, led by both regulated & emerging markets
* However, rebound appears largely priced in
* Reduce FY22/23E EPS by 4/5% on lower regulated market sales
* Maintain Neutral, TP cut to Rs 908 from Rs 942
